Q-State Biosciences Presents at the 2021 Neuroimmunology Drug Development Summit

by Business Wire • 2021/04/29 • 0 Comments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Q-State Biosciences announces new data presented at the 2021 Neuroimmunology Drug Development Summit.

← Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock

Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease →